Stockscreener 앱 받기
0.72
0.26%
0.0019
시간 외 거래:
.72
Equillium Inc 주식(EQ)의 최신 뉴스
Why Investors Shouldn't Be Surprised By Equillium, Inc.'s (NASDAQ:EQ) 35% Share Price Plunge - Simply Wall St
Equillium CFO Jason Keyes sells $7,000 in stock By Investing.com - Investing.com UK
Equillium CFO Jason Keyes sells $7,000 in stock - Investing.com
Equillium’s Q3 Financials and Clinical Progress in Focus - TipRanks
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates - The Bakersfield Californian
Equillium Q3 Revenue Jumps 37% to $12.2M, Slashes Net Loss as Pipeline Advances | EQ Stock News - StockTitan
Equillium to Present at the Stifel Healthcare Conference - The Bakersfield Californian
Equillium to Present Clinical Pipeline Updates at Stifel Healthcare Conference | EQ Stock News - StockTitan
Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer - BioSpace
Equillium Reveals Breakthrough Immune Response Data at Major Cancer Conference | EQ Stock News - StockTitan
Equillium, Inc. (EQ) to Report Q3 Results: Wall Street Expects Earnings Growth - MSN
Equillium keeps equilibrium in GVHD after Ono no-go - BioWorld Online
Equillium says Ono not acquiring itolizumab, stock craters 36% - MSN
Ono says no to Equillium’s itolizumab - The Pharma Letter
Jones Trading Downgrades Equillium (EQ) - MSN
Equillium retains rights to itolizumab after Ono's option expires - Investing.com India
Equillium shares downgraded to hold from buy By Investing.com - Investing.com Canada
Equillium shares downgraded to hold from buy - Investing.com India
Equillium says Ono not acquiring itolizumab, stock craters 36% (NASDAQ:EQ) - Seeking Alpha
Equillium Maintains Rights to Itolizumab Following Ono Partnership - Business Wire
Equillium COO Christine Zedelmayer sells $18,750 in stock - Investing.com
Equillium COO Christine Zedelmayer sells $18,750 in stock By Investing.com - Investing.com Australia
LogoEquillium Maintains Rights to Itolizumab Following Ono Partnership - Business Wire
Insider Sale: Sr. Vice President and COO Christine Zedelmayer Se - GuruFocus.com
Alto Ingredients And 2 Other US Penny Stocks To Watch Closely - Simply Wall St
Moleculin Biotech (NASDAQ:MBRX) versus Equillium (NASDAQ:EQ) Financial Comparison - Defense World
Renaissance Technologies LLC Acquires 91,200 Shares of Equillium, Inc. (NASDAQ:EQ) - Defense World
Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer - StockTitan
Equillium CFO Jason Keyes sells $8,100 in company stock By Investing.com - Investing.com South Africa
Equillium CFO Jason Keyes sells $8,100 in company stock - Investing.com India
Lacklustre Performance Is Driving Equillium, Inc.'s (NASDAQ:EQ) 28% Price Drop - Simply Wall St
Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
Equillium executive sells $32,985 in stock - Investing.com India
Equillium executive sells $32,985 in stock By Investing.com - Investing.com Australia
Equillium collaborates with Vivtex for oral formulation of autoimmune therapy - Yahoo Finance
Vivtex Enters New Research Agreement with Equillium to Develop GI-targeted Formulations for its First-in-Class Oral, Bi-Specific Peptide Therapy - ForexTV.com
Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit - StockTitan
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Wall Street analysts’ outlook for Equillium Inc (EQ) - SETE News
Equillium Inc’s Market Journey: Closing Weak at 1.07, Down -0.93 - The Dwinnex
How should investors view Equillium Inc (EQ)? - US Post News
Equillium Inc Inc. (EQ) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference - StockTitan
Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26 - Business Wire
Q3 2024 Earnings Forecast for Equillium, Inc. (NASDAQ:EQ) Issued By HC Wainwright - Defense World
Equillium, Inc. (NASDAQ:EQ) Forecasted to Post FY2024 Earnings of $0.62 Per Share - Defense World
Equillium’s (EQ) Buy Rating Reiterated at HC Wainwright - Defense World
Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience - Marketscreener.com
Equillium Second Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Equillium (NASDAQ:EQ) Issues Quarterly Earnings Results, Beats Estimates By $0.16 EPS - Defense World
0.93%
3.55%
자본화:
|
볼륨(24시간):